Key result
Higher FIB-4 index linked to ~19% higher risk of contrast-associated acute kidney injury.
Why the study?
Contrast-associated acute kidney injury (CA-AKI) is a clinically important complication of coronary angiography in NSTEMI patients, and it remained unclear whether the FIB-4 index and APRI relate to CA-AKI in this setting.
Does the Fibrosis-4 (FIB-4) index or aspartate aminotransferase-to-platelet ratio index (APRI) predict contrast-associated acute kidney injury in patients with NSTEMI undergoing coronary angiography?
Observational (n=771)
Does the Fibrosis-4 (FIB-4) index or aspartate aminotransferase-to-platelet ratio index (APRI) predict contrast-associated acute kidney injury in patients with NSTEMI undergoing coronary angiography?
In NSTEMI patients undergoing coronary angiography, admission FIB-4 is independently associated with contrast-associated acute kidney injury and outperforms APRI, though its overall discrimination is modest and incremental value over the Mehran score is not statistically significant.
Answers are grounded in this paper and cite their sources.
FIB-4 may aid CA-AKI risk stratification in NSTEMI; leaves open incremental value over Mehran score without prospective validation.
Background/Objectives: In patients with non-ST-segment elevation myocardial infarction (NSTEMI), contrast-associated acute kidney injury (CA-AKI) is a clinically important complication of coronary angiography. Whether the Fibrosis-4 (FIB-4) index and aspartate aminotransferase-to-platelet ratio index (APRI) relate to CA-AKI in this setting is unclear. We compared the associations of both indices with CA-AKI. Methods: We retrospectively analyzed 771 patients with NSTEMI who underwent coronary angiography from May 2020 to May 2025. CA-AKI was identified from changes in serum creatinine 48–72 h after contrast administration. Both indices were derived from admission laboratory values. Associations were evaluated using separate multivariable logistic regression models. Discrimination was compared using the paired DeLong test, and the incremental performance of FIB-4 beyond the Mehran score was explored. Results: Overall, 97 patients (12.6%) developed CA-AKI. In the primary adjusted model, FIB-4 was associated with CA-AKI (odds ratio 1.19, 95% confidence interval 1.04–1.36; p = 0.013), but APRI was not. FIB-4 showed modest discrimination but a significantly higher area under the receiver operating characteristic curve (AUC) than APRI (0.614 versus 0.535; DeLong p < 0.001). Adding FIB-4 to the Mehran score improved model fit (likelihood-ratio p = 0.009), but the increase in AUC from 0.646 to 0.666 was not statistically significant (DeLong p = 0.100). Sensitivity analyses showed that the association varied with covariate adjustment. Conclusions: FIB-4 was associated with CA-AKI in the primary adjusted model and showed higher discrimination than APRI. These findings support further investigation of FIB-4 as a potential adjunct to renal risk assessment, although its modest discrimination and uncertain incremental clinical value require independent validation.
No takes yet. Share an insight, caveat, or question.
Genç et al. (2026) conducted an observational in Non-ST-segment elevation myocardial infarction (NSTEMI) (n=771). Fibrosis-4 (FIB-4) index vs. Aspartate aminotransferase-to-platelet ratio index (APRI) was evaluated on Contrast-associated acute kidney injury (CA-AKI) 48-72 h after contrast administration (OR 1.19, 95% CI 1.04-1.36, p=0.013). FIB-4 index was associated with contrast-associated acute kidney injury (OR 1.19; 95% CI 1.04-1.36; p=0.013) and showed higher discrimination than APRI (AUC 0.614 vs 0.535; p<0.001).
Synapse has enriched 10 related papers. Consider them for comparative context: